Synosis will acquire five candidates, including four in Phase I.

Synosis Therapeutics acquired five drug candidates targeting the central nervous system from Roche. Of the five Roche-discontinued compounds are Phase I molecules. “By partnering with Synosis, we’re giving these potential medicines the best chance of success by creatively extending our innovation base in an important therapeutic area,” comments Peter Hug, Roche’s global head of Pharma Partnering.


Under the terms of the deal, Synosis will be responsible for the clinical development of all five candidates. Roche retains the right to opt-in to two preselected programs. Synosis has full commercial rights to three preselected programs.

Previous articleAffinium Awarded $4.8M Biodefense Contract
Next articleBiogen Idec Takes Over Syntonix for $40M